Newron Pharmaceuticals SpA (XSWX:NWRN) Short-Term Debt: CHF34.96 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NWRN Newron Pharmaceuticals SpA XSWX:NWRN
75 GF Score
Price CHF12.10
GF Value CHF13.10
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Short-Term Debt?

Newron Pharmaceuticals SpA XSWX:NWRN +3.42% 75 Short-Term Debt is CHF34.96 Mil as of Dec. 2025. GuruFocus rates XSWX:NWRN with a GF Score™ of 75/100 and a GF Value™ of CHF13.10 (Fairly Valued). The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA's Short-Term Debt for the quarter that ended in Dec. 2025 was CHF34.96 Mil.

Newron Pharmaceuticals SpA's quarterly Short-Term Debt increased from Dec. 2024 (CHF12.52 Mil) to Jun. 2025 (CHF31.68 Mil) and increased from Jun. 2025 (CHF31.68 Mil) to Dec. 2025 (CHF34.96 Mil).

Newron Pharmaceuticals SpA's annual Short-Term Debt declined from Dec. 2023 (CHF21.01 Mil) to Dec. 2024 (CHF12.52 Mil) but then increased from Dec. 2024 (CHF12.52 Mil) to Dec. 2025 (CHF34.96 Mil).

Newron Pharmaceuticals SpA Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Newron Pharmaceuticals SpA Short-Term Debt Related Terms

Newron Pharmaceuticals SpA Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Short-Term Debt Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 21.01 12.52 34.96

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.01 0.00 12.52 31.68 34.96
XSWX:NWRN
75GF Score
Newron Pharmaceuticals SpA XSWX:NWRN
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of CHF34.96 Mil mean?
Newron Pharmaceuticals SpA (XSWX:NWRN) has a Short-Term Debt of CHF34.96 Mil as of Dec. 2025.
Is Newron Pharmaceuticals SpA's Short-Term Debt too high?
Newron Pharmaceuticals SpA's current Short-Term Debt is CHF34.96 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Short-Term Debt compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Short-Term Debt of CHF34.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Newron Pharmaceuticals SpA's current Short-Term Debt is CHF34.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF13.10, compared to a current price of CHF12.10 — trading 7.6% below its estimated fair value. The current Short-Term Debt is CHF34.96 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current Short-Term Debt is CHF34.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of CHF12.10 is trading 7.6% below its estimated GF Value™ of CHF13.10. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for XSWX:NWRN:

  • Short-Term Debt: CHF34.96 Mil
  • GF Value™: CHF13.10 vs. price of CHF12.10 (7.6% below fair value)
  • GF Score™: 75/100 with 5 warning signs

No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Other Exchanges NWRNz:UK0QOI:UKNP5:Germany
Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
75GF Score

Get the complete analysis for XSWX:NWRN

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF12.10
Price
CHF13.10
GF Value